In Entos Pharmaceuticals’ Edmonton lab, there’s excitement over how close the company is getting to developing a made-in-Canada COVID-19 vaccine. There’s also dismay.
With more federal help, Entos’ CEO John Lewis says they could be much closer to a vaccine than they are.
“We were hoping that the federal government would have stepped up early like other governments have done for their manufacturers and innovators.
“We just haven’t seen that. It’s very frustrating.”
READ MORE:
Alberta slams federal rollout of COVID-19 vaccine as positivity rate sits at 3.9%
In March of last year, Lewis says Entos decided to change direction. The company had been working on cancer treatments and vaccines but when the COVID-19 pandemic hit, Entos focused on developing a vaccine.
They had the people and the know-how. What they didn’t have was a way to actually make the vaccine.
Lewis estimated Entos would need about $50 million to develop the company’s manufacturing capacity.
The company has put profits and its own money towards that sum.
Officials also asked the federal government for grants and received some money. Lewis says little has been smooth about the process.
“We also applied for manufacturing support in June, learned in October we were successful.
“We negotiated the contract back and forth. We found out just a week ago that they’d cancelled that contract.”
READ MORE:
Edmonton company receives federal funds to develop COVID-19 vaccine
That cancellation means the company has gone from expecting to produce between 1 and 4 million doses per day when ready to 25,000 doses per day.
...
(Remainder of article at link above)